What Is MK-677?
MK-677 (ibutamoren mesylate) is a non-peptide, orally active ghrelin receptor agonist and growth hormone secretagogue originally developed by Merck & Co. It selectively mimics the action of ghrelin, an endogenous gut-derived peptide, at the growth hormone secretagogue receptor (GHS-R1a), stimulating pulsatile GH release from the pituitary. Unlike injectable GH secretagogue peptides such as GHRP-2 or GHRP-6, MK-677's non-peptide structure renders it orally bioavailable, a property that significantly influenced its research trajectory.
MK-677 is one of the more extensively studied growth hormone secretagogues in human clinical research, with published data from trials examining its effects on GH/IGF-1 axis parameters, body composition, bone mineral density, and sleep architecture across multiple populations including healthy volunteers, elderly subjects, and patients with specific metabolic conditions.
Mechanism of Action
MK-677 acts as a full agonist at GHS-R1a (also known as the ghrelin receptor), which is expressed in the hypothalamus and pituitary gland. Receptor activation stimulates GH secretion through two converging mechanisms: direct stimulation of somatotroph cells in the anterior pituitary and suppression of somatostatin release in the hypothalamus, the endogenous inhibitor of GH secretion. The net result is enhanced GH pulse amplitude with maintenance of physiological GH pulsatility, distinguishing MK-677's pharmacological profile from continuous GH infusion or exogenous GH administration.
Downstream IGF-1 elevation follows GH secretion with a delay of 6–12 hours, consistent with hepatic IGF-1 synthesis in response to GH signaling.
Landmark Clinical Research
The foundational human pharmacology study for MK-677 was published by Murphy et al. in the New England Journal of Medicine (1998). This double-blind, placebo-controlled crossover trial in 32 healthy elderly men and women (ages 64–81) demonstrated that twice-daily oral MK-677 produced sustained, dose-dependent increases in GH pulse amplitude and IGF-1 levels over a two-month period. Notably, the study reported that MK-677 increased GH secretion to levels equivalent to those observed in young adults, framing the compound as a potential research tool for studying GH replacement biology in aging.
Body Composition and Lean Mass Research
Nass et al. (2008) in the Journal of Clinical Endocrinology & Metabolism published results from a randomized controlled trial examining MK-677 in 65 elderly adults over two years. The study found that MK-677 significantly increased lean body mass and appendicular lean mass, as measured by DEXA, without significant changes in fat mass. Grip strength also showed improvement in the treatment group, consistent with the anabolic effects of GH/IGF-1 axis activation on skeletal muscle. These findings have been cited as some of the most direct human evidence for the lean mass effects of GH secretagogue signaling.
Bone Mineral Density Research
GH and IGF-1 are known regulators of bone remodeling, and research has examined MK-677's effects on bone metabolism. Murphy et al. and subsequent studies reported increases in bone turnover markers (osteocalcin, bone-specific alkaline phosphatase) in subjects receiving MK-677, consistent with GH/IGF-1-stimulated bone remodeling. Long-term studies have also reported improvements in bone mineral density in specific populations, though the magnitude of these effects varies across study designs.
Sleep Architecture Research
MK-677 has been examined for its effects on sleep given the well-established relationship between GH secretion and slow-wave (deep) sleep. Studies have reported that MK-677 increases REM sleep duration and improves sleep quality measures in healthy elderly subjects, an effect attributed to its GHS-R1a activity, as ghrelin receptors are expressed in hypothalamic nuclei regulating sleep-wake cycles. This makes MK-677 a useful tool compound for researchers studying the intersection of GH secretion and sleep biology.
Glucose Metabolism Considerations
Research has consistently noted that MK-677 increases fasting blood glucose and insulin levels, consistent with the known insulin-antagonizing effects of GH. Studies have observed that insulin sensitivity decreases modestly in subjects receiving MK-677, particularly at higher doses. This metabolic effect has been a consistent finding across trials and represents an important variable to monitor in research protocols examining MK-677's effects.
Current Research Status
MK-677 progressed through Phase II clinical trials for indications including hip fracture recovery, GH deficiency, and muscle wasting, but has not received FDA approval for any indication. The published human clinical data provide a well-characterized pharmacological and safety profile that distinguishes MK-677 from many research compounds with exclusively preclinical data.
Selected References
- Murphy MG, et al. (1999). Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. Journal of Bone and Mineral Research, 14(7):1182–8.
- Murphy MG, et al. (1998). MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. Journal of Clinical Endocrinology & Metabolism, 83(2):320–325.
- Nass R, et al. (2008). Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults. Annals of Internal Medicine, 149(9):601–611.
- Svensson J, et al. (1998). Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure. Journal of Clinical Endocrinology & Metabolism, 83(2):362–369.
- Copinschi G, et al. (1997). Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology, 66(4):278–286.